

<b>Antibiotic</b>	<b><i>K. pneumoniae</i> (n=599) (%)</b>	<b><i>E. coli</i> (n=599) (%)</b>	<b><i>K. pneumoniae</i> vs. <i>E. coli</i> P-value</b>	<b><i>E. coli</i> (n=3047) *</b>	<b>P-value <i>E. coli</i> matched cohort versus all <i>E. coli</i></b>
Ciprofloxacin	47 (8)	103 (17)	<b>&lt;0.001</b>	593 (19)	0.20
Trimethoprim/ sulfa	62 (10)	172 (29)	<b>&lt;0.001</b>	898 (29)	0.73
Cefotaxime	11 (2)	40 (7)	<b>&lt;0.001</b>	208 (7)	0.90
Ceftazidime	15 (3)	35 (6)	<b>0.004</b>	193 (6)	0.65
Gentamicin	13 (2)	40 (7)	<b>&lt;0.001</b>	194 (6)	0.63
Piperacillin/ tazobactam	35 (6)	43 (7)	0.35	298 (10)	<b>0.046</b>
Meropenem	2 (0)	0 (0)	0.50	0 (0)	1.00
Multidrug- resistance (I or R $\geq$ 3 classes of antibiotics)	15 (3)	57 (10)	<b>&lt;0.001</b>	209 (7)	<b>0.022</b>
ESBL (including CPE)	9 (2)	36 (6)	<b>&lt;0.001</b>	172 (6)	0.72
CPE**	1 (0)	0 (0)	1.00	0 (0)	1.00
Isolates with resistance to any group above	106 (18)	218 (36)	<b>&lt;0.001</b>	1226 (40)	0.08

Bold = P<0.05

\* includes children and one isolate/patient/year

\*\* VIM, CTX-M-1, CMY-2 in genotypic analysis